Immunome Stock Quote IMNM - Stock Price, News, Charts, Message Board, Trades

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Immunome Inc (IMNM) Quote

Immunome Inc (IMNM)

0.00

0.00

(0.00%)

Closed June 30 4:00PM

Delayed by 15 minutes

0.00

0.00

(0.00%)

After Hours: -

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Current Price

-

Bid

-

Ask

-

Volume

-

0.00 Day's Range 0.00

5.68 52 Week Range 30.958

Market Cap

Previous Close

-

Open

-

Last Trade

Last Trade Time

Financial Volume

-

VWAP

-

Average Volume (3m)

896,742

Shares Outstanding

59,968,868

Dividend Yield

-

PE Ratio

-6.79

Earnings Per Share (EPS)

-1.78

Revenue

14.02M

Net Profit

-106.81M

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.immunome.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Immunome Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNM. The last closing price for Immunome was -. Over the last year, Immunome shares have traded in a share price range of $ 5.68 to $ 30.958.

Immunome currently has 59,968,868 shares outstanding. The market capitalization of Immunome is $725.02 million. Immunome has a price to earnings ratio (PE ratio) of -6.79.

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	12.68	12.99	11.07	1550967	12.12130087	CS
4	0	0	15.32	16.76	11.07	1067972	13.60407181	CS
12	0	0	20.17	21.72	11.07	896742	14.78204559	CS
26	0	0	10.42	30.958	10.33	790691	17.90810993	CS
52	0	0	5.68	30.958	5.68	490763	15.89333814	CS
156	0	0	18.17	30.958	2.09	237965	15.28146292	CS
260	0	0	15.66	63.78	2.09	220412	17.0621633	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ASNSActelis Networks Inc	$ 2.3599 (59.45%)	71.61M
COSMCosmos Health Inc	$ 1.05 (54.64%)	81.3M
LUCYInnovative Eyewear Inc	$ 0.5036 (52.61%)	364.85M
NNENano Nuclear Energy Inc	$ 23.43 (44.45%)	9.41M
NBSTWNewbury Street Acquisition Corporation	$ 0.0613 (39.32%)	19.62k
CINGCingulate Inc	$ 0.315 (-46.06%)	2.36M
ACCDAccolade Inc	$ 3.53 (-44.76%)	14.63M
BTOGBit Origin Ltd	$ 2.95 (-44.55%)	3.3M
NXLNexalin Technologies Inc	$ 1.695 (-42.74%)	4.31M
APVOAptevo Therapeutics Inc	$ 0.309899 (-39.81%)	2.37M
LUCYInnovative Eyewear Inc	$ 0.5036 (52.61%)	364.85M
NVDANVIDIA Corporation	$ 123.54 (-0.36%)	315.71M
FFIEFaraday Future Intelligent Electric Inc	$ 0.5052 (-15.80%)	197.64M
SQQQProShares UltraPro Short QQQ	$ 8.28 (1.85%)	155.74M
PLUGPlug Power Inc	$ 2.32 (-5.69%)	121.64M

Monksdream

Monksdream 3 months ago

IMNM 10Q due 3/22

Monksdream

Monksdream 4 months ago

IMNM new 52 week hi

Monksdream

Monksdream 5 months ago

IMNM new 52 week high

OncoJock

OncoJock 7 months ago

Agree.

Wish there were most posts on this board.

Wondering who might be the next big customer to sign a major discovery and commercialization contract with IMNM, after AbbVie?

Also wondering if IMNM is doing any discovery/testing/research related to bispecific antibodies, as opposed to antibody-drug conjugates. Bispecifics are HOT HOT HOT in lymphoma and myeloma.

-- OJ

OncoJock

OncoJock 7 months ago

Laster

Laster 9 months ago

Hopefully the vote passed.
I think this biotech combined company can be a huge success.
Siegall has proven he can build a biotech company.
This will be fun to watch.

Laster

Laster 9 months ago

I believe merger news tomorrow along with huge financing.
Clay B. Siegall To become chairman and CEO of combined company.
He founded Seagen which just sold for $40 billion to Pfizer.
Their innovative technology from Professor Philip S. Low (Purdue University).
Look at Professor Low accomplishments. Unreal.
Watching closely because this might become a huge biotech company.

wiwineguy

wiwineguy 1 year ago

Ha, sold in fall of 21 for $25.

makinezmoney

makinezmoney 1 year ago

$IMNM: Now 10.40 !!!!!!!!!!!

Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

GO $IMNM

makinezmoney

makinezmoney 1 year ago

$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50

Offfffffffffff she goes.

Nice boomer

GO $IMNM

Awl416

Awl416 1 year ago

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

wiwineguy

wiwineguy 3 years ago

you don't know crap majorbankz. you keep saying i "heard" this, and I "heard" that. can you be any more vague. stfu

Harbor6460

Harbor6460 3 years ago

They cannot dilute on the bid. Only the ask

Pedro2004

Pedro2004 3 years ago

Pulled down to under $20.00

Pedro2004

Pedro2004 3 years ago

They pulled this down to under $21.00

I'm back-in at $21.00

Major_Bankz

Major_Bankz 3 years ago

$22.50 U worry too much, should be $25+ this afternoon IMO

Pedro2004

Pedro2004 3 years ago

I thought this was going to break today. But it' just jumped over $22 -- let's see if that holds.

Pedro2004

Pedro2004 3 years ago

This run could have broke $30 today. But the company killed-it.

Major_Bankz

Major_Bankz 3 years ago

yep, shorties portfolio will get destroyed here.

Pedro2004

Pedro2004 3 years ago

The dilution is going to kill this run.

Pedro2004

Pedro2004 3 years ago

Looks like the company is dumping shares on the bid.

Major_Bankz

Major_Bankz 3 years ago

I don't think PFE and MRNA can claim the same effectiveness for DELTA, plus time to buy is during development not after just like when MRNA was at $20. IMO

Major_Bankz

Major_Bankz 3 years ago

Delta is a BIG problem, IMNM may catch up to PFE and MRNA. IMO

Major_Bankz

Major_Bankz 3 years ago

Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.

Major_Bankz

Major_Bankz 3 years ago

IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Delayed Upgrade Clock